Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Arvinas Inc (ARVN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Arvinas's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
33.45 0.01    0.03%
- Closed. Currency in USD ( Disclaimer )
After Hours
35.12
+1.67
+4.99%
- Real-time Data
Type:  Equity
Market:  United States
  • Volume: 503,954
  • Bid/Ask: 22.63 / 39.00
  • Day's Range: 32.80 - 33.91
Arvinas 33.45 0.01 0.03%

Arvinas Inc Company Profile

 
Get an in-depth profile of Arvinas Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

415

Equity Type

ORD

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Contact Information

Address 5 Science Park 395 Winchester Avenue
New Haven, 06511
United States
Phone 203 535 1456
Fax -

Top Executives

Name Age Since Title
Linda Cathavina Bain 53 2020 Independent Director
Sunil Agarwal 53 2023 Independent Director
Bradley T. Hyman - 2022 Member of Scientific Advisory Board
John G. Houston 63 2017 Chairperson, CEO & President
John D. Young 58 2022 Independent Director
Everett V. Cunningham 57 2022 Independent Director
Michelle Arkin - 2023 Member of Scientific Advisory Board
Susan Kaech - 2022 Member of Scientific Advisory Board
Edward Moore Kennedy 62 2018 Independent Director
Benjamin G. Neel - 2019 Member of Scientific Advisory Board
Laurie Smaldone Alsup 69 2019 Independent Director
Leslie V. Norwalk 58 2019 Independent Director
Adam L. Boxer - 2019 Member of Scientific Advisory Board
Briggs W. Morrison 63 2018 Lead Independent Director
Wendy L. Dixon 68 2020 Independent Director
Lillian L. Siu - 2019 Member of Scientific Advisory Board
Lennart Mucke - 2019 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ARVN Comments

Write your thoughts about Arvinas Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Dusko Pavlovic
Dusko Pavlovic Feb 01, 2022 8:24AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
let's see Goldman recommended @71.49
Wojciech Stefaniak
Wojciech Stefaniak Feb 01, 2022 8:24AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
They are paid, so don't follow these inept, so called, analysts.
Dusko Pavlovic
Dusko Pavlovic Feb 01, 2022 8:24AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
let's see Goldman recommended @71.49
Marat Aysin
Marat Aysin Jul 26, 2021 10:34AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
wonder if it will hit the targets
Ab High
Ab High Dec 14, 2020 8:03AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
no reason for that
Kevin Durant
Kevin Durant Dec 14, 2020 7:30AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Whats happening?
Sandeep Ravindranathan
Sandeep Ravindranathan Dec 14, 2020 7:30AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://endpts.com/news-briefing-arvinas-shares-double-on-interim-data-for-two-cancer-programs-uk-biopharma-snaps-up-oncology-cro/
현수 김
현수 김 Nov 30, 2020 11:20AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Dec3
Novice Investor
InvestForSuccess Feb 05, 2020 3:09PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
who the heck is buying this?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email